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Abstract
Background: Platelet P2Y12 antagonist ticagrelor reduces mortality after acute myo-
cardial infarction (AMI) compared to clopidogrel, but the underlying mechanism is 
unknown. Because activated platelets, leukocytes, and endothelial cells release pro-
inflammatory and prothrombotic extracellular vesicles (EVs), we hypothesized that 
the release of EVs is more efficiently inhibited by ticagrelor compared to clopidogrel.
Objectives: We compared EV concentrations and EV procoagulant activity in plasma 
of patients after AMI treated with ticagrelor or clopidogrel.
Methods: After percutaneous coronary intervention, 60 patients with first AMI were 
randomized to ticagrelor or clopidogrel. Flow cytometry was used to determine con-
centrations of EVs from activated platelets (CD61+, CD62p+), fibrinogen+, phosphati-
dylserine (PS+), leukocytes (CD45+), endothelial cells (CD31+, 146+), and erythrocytes 
(CD235a+) in plasma at randomization, after 72 hours and 6 months of treatment. A 
fibrin generation test was used to determine EV procoagulant activity.
Results: Concentrations of platelet, fibrinogen+, PS+, leukocyte, and erythrocyte 
EVs increased 6 months after AMI compared to the acute phase of AMI (P ≤ .03). 
Concentrations of platelet EVs were lower on ticagrelor compared to clopidogrel after 
6 months (P = .03). Concentrations of fibrinogen+, PS+, and leukocyte EVs were lower 
on ticagrelor compared to clopidogrel both after 72 hours and 6 months (P ≤ .03). 
Concentrations of endothelial EVs and EV procoagulant activity did not differ be-
tween patient groups and over time (P ≥ .17).
Conclusions: Ticagrelor attenuates the increase of EV concentrations in plasma after 
acute myocardial infarction compared to clopidogrel. The ongoing release of EVs 
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1  | BACKGROUND
Atherosclerosis is a chronic inflammatory disease of the vessel 
wall leading to acute myocardial infarction (AMI).1 In the course of 
AMI, activated platelets, leukocytes, and endothelial cells (ECs) re-
lease extracellular vesicles (EVs).2 A recent systematic review with 
meta-analysis of seven clinical studies demonstrated that plasma 
concentrations of EVs are two-fold higher in patients with AMI, 
compared to healthy controls.3 EVs are membrane-enclosed cell-
derived particles exposing proteins derived from the parent cell. 
Although a generic EV marker is lacking,4 proteins binding phos-
phatidylserine (PS) are commonly used to stain ~50% of all plasma 
EVs.5 Because PS facilitates the assembly of tenase and pro-
thrombinase complexes in the presence of calcium ions, thereby 
accelerating thrombin formation, PS-exposing EVs are considered 
procoagulant.6 EVs also expose specific cell markers (clusters of 
differentiation, CD) revealing their cellular origin. For example, EVs 
from activated platelets expose the identification marker glyco-
protein (GP) IIb/IIIa (CD41/CD61), and platelet activation markers, 
such as P-selectin (CD62p) and fibrinogen.7 Platelet EVs expos-
ing P-selectin or fibrinogen likely contribute to inflammation and 
thrombosis. For example, P-selectin binds to P-selectin glycopro-
tein ligand-1 on monocytes, leading to production and exposure of 
tissue factor (TF) on monocytes and secretion of pro-inflammatory 
cytokines.8 Fibrinogen binds both to the CD11b/CD18 recep-
tor (Mac-1) on monocytes, thereby activating monocytes, and to 
the activated GPIIb/IIIa, thereby enabling platelet aggregation.9 
Altogether, EVs exposing PS, P-selectin, and/or fibrinogen may (a) 
contribute to thrombus formation, and (b) be involved in maintain-
ing the chronic inflammatory state of the vessel wall after AMI. 
Therefore, inhibition of EV release might be a unique opportunity 
for combined antithrombotic and anti-inflammatory treatment 
strategy after AMI.10
Because AMI is caused by activation of platelets on a ruptured 
atherosclerotic plaque, dual antiplatelet therapy with aspirin and 
antagonist of the platelet P2Y12 receptor for adenosine diphos-
phate (ADP) has become the standard of care to prevent recurrent 
thrombotic events after AMI.11 The P2Y12 receptor antagonist 
ticagrelor provides faster and more pronounced and consistent 
inhibition of platelet aggregation than clopidogrel, the previous 
standard antiplatelet treatment after AMI.12 Whereas both clopi-
dogrel and ticagrelor inhibit the platelet P2Y12 receptor for ADP, 
only ticagrelor inhibits the reuptake of adenosine, thus increasing 
the concentration of adenosine in the bloodstream.13 Both inhibi-
tion of the P2Y12 receptor and activation of the A2a receptor by 
adenosine inhibit platelet activation.14 Ticagrelor reduces the rate 
of recurrent thrombotic events and mortality compared to clopi-
dogrel, as shown in the PLATO (Platelet Inhibition and Patients 
Outcomes) study, confirming that the extent of platelet inhibition 
is associated with prognosis.15 However, improved prognosis on ti-
cagrelor cannot be explained solely by ticagrelor anti-aggregatory 
effect, because the anti-aggregatory effect is achieved directly 
after ticagrelor administration, whereas reduction in mortality 
starts after at least 2 weeks and increases with the length of treat-
ment.15 Thus, likely other mechanisms than inhibition of platelet 
aggregation contribute to the benefits of long-term treatment with 
ticagrelor.
We hypothesized that ticagrelor decreases plasma concen-
trations of prothrombotic and pro-inflammatory EVs compared to 
clopidogrel, which potentially contributes to improved prognosis in 
patients treated with ticagrelor. Because P2Y12 receptors are ex-
posed also on leukocytes,16,17 and vascular ECs,18,19 ticagrelor and 
clopidogrel might affect the release of EVs from leukocytes and ECs 
as well.
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despite antiplatelet therapy might explain recurrent thrombotic events after AMI and 
worse clinical outcomes on clopidogrel compared to ticagrelor.
K E Y W O R D S
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Essentials
• Activated platelets, leukocytes, and endothelial cells re-
lease extracellular vesicles (EVs)
• A randomized controlled trial was performed to compa-
reEV concentrations on ticagrelor or clopidogrel.
• Flow cytometry detectors were calibrated in compara-
ble units to ensure reliable EV analysis.
• Ticagrelor attenuates the increase in platelet and leuko-
cyteEV concentrations compared to clopidogrel.
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2  | OBJEC TIVES
The goal of the AFFECT EV (Antiplatelet therapy eFFECT on 
Extracellular Vesicles) trial was to compare the effect of ticagrelor 
and clopidogrel on the concentration and procoagulant activity of 
circulating EVs in patients after AMI.
3  | METHODS
3.1 | Study design
AFFECT EV was an investigator-initiated, single-center, randomized 
study conducted at the First Chair and Department of Cardiology, 
Medical University of Warsaw, Poland, in collaboration with 
the Vesicle Observation Centre, Amsterdam University Medical 
Centres (UMC), the Netherlands. The study protocol, designed 
in compliance with the Declaration of Helsinki, was approved by 
the Ethics Committee of Medical University of Warsaw (approval 
number: KB/112/2016), registered in the ClinicalTrials database 
(NCT02931045) and published previously.20 All participants pro-
vided written informed consent.
3.2 | Selection of participants
Study inclusion and exclusion criteria are listed in Table 1. Patients 
were eligible for enrollment if they (a) were admitted to the hospital 
due to the first ST-segment elevation of acute myocardial infarction 
(STEMI) or non-STEMI (NSTEMI) with an onset of symptoms dur-
ing the previous 24 hours, and (b) underwent percutaneous coro-
nary intervention (PCI) with stent implantation. When study was 
initiated, the majority of patients with STEMI were pretreated with 
clopidogrel before hospital admission. Hence, only patients who re-
ceived a loading dose of clopidogrel (600 mg) were enrolled to obtain 
a homogenous group. STEMI was diagnosed based on persistent ST-
segment elevation of at least 0.1 mV in at least two contiguous elec-
trocardiography leads or a new left bundle-branch block.21 NSTEMI 
was diagnosed as ST-segment changes on electrocardiogram (ECG) 
including ST depression, transient ST elevation, and T-wave changes, 
along with a positive cardiac troponin test indicating myocardial ne-
crosis in patients with the typical anginal chest pain.22
3.3 | Randomization and blinding
The trial schedule is presented in Figure 1A. Within 24 hours PCI, 
patients were randomized in a 1:1 ratio either to replace clopidogrel 
with ticagrelor (study group) or to continue treatment with clopi-
dogrel (control group). Block randomization with fixed block size of 
eight without stratification was conducted using a sealed envelope 
system by an independent operator (MP), who was otherwise not in-
volved in sample collection and analysis. During the trial, participants 
were identified by an individual randomization number, and samples 
were coded with a unique sample number. All samples were meas-
ured in one block by an operator blinded to treatment-related data 
(AG). Flow cytometry data analysis was performed by an independ-
ent operator, blinded to any clinical data (EvdP). Statistical analysis 
was performed by an independent operator (MB).
3.4 | Study treatment
Ticagrelor was given in a loading dose of 180 mg, followed by a main-
tenance dose of 90 mg twice daily. Clopidogrel was continued with 
a maintenance dose of 75 mg daily. At discharge, patients received 
either ticagrelor or clopidogrel for 6 months of treatment, when 
a follow-up visit was scheduled. In addition, all patients received 
75 mg aspirin and at least 10 mg atorvastatin once daily. All patients 
received standard treatment after AMI according to the guidelines, 
including β-blocker, angiotensin-converting enzyme inhibitor or an-
giotensin receptor blocker, aldosterone receptor antagonist, and 
protein pump inhibitor, depending on the individual clinical charac-
teristics and comorbidities.21
3.5 | Clinical data collection
As baseline, we defined the moment of randomization. The follow-
ing data were collected at baseline: demographics (age, gender), 
body mass index, diagnosis at admission, cardiovascular risk factors 
(smoking, hypertension, dyslipidaemia, diabetes), history of cardio-
vascular disease (stroke, carotid artery disease, peripheral artery 
disease). In addition, routine laboratory parameters were recorded. 
Before discharge, patients underwent detailed echocardiographic 
evaluation and left ventricle ejection fraction and global longitudinal 
strain was recorded. At discharge, pharmacotherapy was recorded. 
At the follow-up visit, compliance was checked by counting of tab-
lets, pharmacotherapy was recorded again, and data regarding major 
adverse cardiovascular events (recurrent AMI, need for urgent re-
vascularization, recurrent hospital admission) and bleeding events 
since the index hospitalisation were recorded.
3.6 | Samples collection and handling
Venous blood was collected from fasting patients (a) 24 hours 
after administration of clopidogrel (randomization ~ baseline), 
(b) 48 hours following randomization to ticagrelor or clopidogrel 
group (matching the length of the hospital stay of patients after 
AMI ~ 72 hours), and (c) 6 months following the index hospitaliza-
tion (follow-up visit). With fasting, we mean ≥8 hours after last 
consumption. Blood was collected and processed by an experi-
enced operator (KP), according to the recent guidelines to study 
EVs.23 Briefly, blood was collected in 10 mL 0.109 mol/L cit-
rated plastic tubes (S-Monovette, Sarstedt) via antecubital vein 
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puncture using a 19-gauge needle, without tourniquet. The first 
2 mL were discarded to avoid pre-activation of platelets. Within 
maximum 15 minutes from blood collection, platelet-depleted 
plasma was prepared by double centrifugation using a Rotina 380 
R equipped with a swing-out rotor and a radius of 155 mm (Hettich 
Zentrifugen). The centrifugation parameters were: 2500 g, 
15 minutes, 20°C, acceleration speed 1, no brake.24 The first 
centrifugation step was done with 10 mL whole blood collection 
TA B L E  1   Eligibility criteria for the study
Inclusion criteria Exclusion criteria
• Age ≥18 years
• Informed consent to participate in the study
• First ST-elevation myocardial infarction (STEMI) or non-STEMI
• PCI with stent implantation
• Administration of the loading dose of clopidogrel (600 mg) prior to 
PCI
• Known coagulopathy
• Active pathological bleeding
• Known history of bleeding disorder
• Suspicion of intracranial haemorrhage
• Need for oral anticoagulation therapy
• Administration of GPIIb-IIIa antagonists
• Cardiogenic shock
• Severe chronic renal failure (eGFR <30 mL/min)
• Severe liver insufficiency
• Infectious disease
• Autoimmune disease
• Neoplasm
• Chronic dyspnea
• Increased risk of bradycardia
• Known pregnancy, breast-feeding, or intention to become pregnant 
during the study period
• Study drug intolerance
• Co-administration of ticagrelor or clopidogrel with strong CYP3A4 
inhibitors
• Participation in any previous study with ticagrelor or clopidogrel
Abbreviations: AMI, acute myocardial infarction; CYP3A4, cytochrome P450 izoenzyme 3A4; eGFR, estimated glomerular filtration rate; GP, 
glycoprotein; PCI, percutaneous coronary intervention
F I G U R E  1   Study design (A) and inclusion and exclusion chart (B). Abbreviations: AMI, acute myocardial infarction; ASA, acetylsalicylic 
acid; CAD, coronary artery disease; GP, glycoprotein; OAC, oral anticoagulation; PCI, percutaneous coronary intervention
60 patients with first AMI 1062 patients screenedfor availability
Excluded:
- 358 recurrent AMI
- 307 stable CAD
- 54 need for OAC
- 23 other reasons
60 patients randomised
(1:1)
30 patients
ticagrelor
27 patients
ticagrelor
28 patients
clopidogrel
Excluded:
-1 withdrew consent
Excluded:
Intention-to-treat analysis
-2 withdrew consent
-2 need for OAC
30 patients
clopidogrel
- 215 administration of ticagrelor
- 109 administration of GP IIb/IIIa
  antagonists
PCI
A B
Informed
consent
Randomization
(1:1)
Ticagrelor 180 mg
+ ASA 75 mg
Ticagrelor 2x 90 mg
+ ASA 1x 75 mg
Follow-up visit
6 months after PCI
72 h after PCI
24 h after PCI
Blood (3)
Blood (2)
Blood (1)
Clopidogrel 1x 75 mg
+ ASA 1x 75 mg
Clopidogrel 75 mg
+ ASA 75 mg
Clopidogrel 600 mg
+ ASA 300 mg
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tubes. Supernatant was collected 10 mm above the buffy coat. 
The second centrifugation step was done with 3.5 mL plasma in 
15 mL polypropylene centrifuge tubes (Greiner Bio-One B.V). 
Supernatant (platelet-depleted plasma) was collected 5 mm above 
the buffy coat, transferred into 5 mL polypropylene centrifuge 
tubes (Greiner Bio-One B.V.), mixed by pipetting, transferred to 
1.5 mL low-protein binding Eppendorfs (Thermo Fisher Scientific), 
and stored in −80°C until analyzed. Prior to analysis, samples were 
thawed for 1 minute in a water bath (37°C) to avoid cryoprecipita-
tion. At each time point, an additional blood sample was collected 
to 2.7 mL hirudin tube to assess platelet reactivity using multiple 
electrode aggregometry (Roche Diagnostics) to check the compli-
ance and response to ASA and P2Y12 antagonists.
3.7 | Endpoints
The primary endpoint was the concentration of EVs from activated 
platelets (exposing CD61 and P-selectin) at 6 months. The secondary 
endpoints were (a) the concentration of platelet EVs exposing CD61 
and P-selectin at 72 hours, and (b) the concentration of platelet EVs 
exposing fibrinogen, leukocyte EVs, and EC-derived EVs at 72 hours 
and 6 months. The tertiary endpoint was procoagulant activity of 
plasma EVs at 72 hours and 6 months, defined as (a) the concentra-
tion of plasma EVs exposing PS, and (b) the TF-dependant proco-
agulant activity of all plasma EVs. The study was not powered for 
mortality or other adverse events.
3.8 | Laboratory assays
3.8.1 | Flow cytometry
Flow cytometry (A60-Micro, Apogee Flow Systems) was used to 
determine the concentration of EV subtypes in platelet-depleted 
plasma. The reported concentrations describe the number of particles 
(a) that exceeded the side scatter threshold, corresponding to a side 
scattering cross section of 10 nm2, (b) with a diameter >200 nm as 
determined by Flow-SR,25 (c) having a refractive index <1.42 to omit 
false positively labeled chylomicrons,26 and (d) that are positive at the 
fluorescence detector(s) corresponding to the used label(s), per mL 
of platelet-depleted plasma. We aimed to label activated platelets 
(CD61+/P-selectin+), fibrinogen+, leukocytes (CD45+), ECs (CD31+/
CD146+), erythrocytes (CD235a+), and all procoagulant EVs (PS+) in 
platelet-depleted plasma. To improve the reproducibility of our EV 
flow cytometry experiments, we (a) applied the new reporting frame-
work for the standardized reporting of EV flow cytometry experi-
ments (MIFlowCyt-EV),27 (b) calibrated all detectors, (c) determined 
the EV diameter and refractive index by the flow cytometry scatter 
ratio (Flow-SR),25 and (d) applied custom-built software to fully auto-
mate data calibration and processing. All relevant details about sample 
preparation, assay controls, instrument calibration, data acquisition, 
and EV characterization are included in the Supporting Information.
3.8.2 | Procoagulant activity of plasma EVs
The procoagulant activity of plasma EVs was determined as the abil-
ity of EVs to generate fibrin in platelet-depleted but EV-containing 
plasma.28 Briefly, after pre-incubation for 5 minutes at 37°C, clot-
ting was initiated by adding CaCl2 (final concentration 2.5 mmol/L). 
Fibrin formation (~clotting) over 1 hour was determined by meas-
uring the optical density (OD; λ = 405 nm) in duplicate on a spec-
trophotometer (SpectraMax) at 37°C. When plasma clots, the OD 
increases. Because TF is the key initiator of the coagulation, and 
because plasma EVs in patients with AMI expose TF,29 the proco-
agulant activity of plasma EVs was evaluated in the absence and 
presence of antibodies against human TF (anti-TF; CLB; clone CLB-
VII-1). Recombinant human TF was used as a positive control, and 
saline was used as a negative control. Only reproducible results 
were taken into account for analysis. At the beginning, the OD was 
set to 0. Clotting was defined as an increase in OD from 0 to >0.2. 
Reproducible results were defined as results which showed clotting 
or lack thereof in duplicate. To obtain the clotting time (Vmax), OD 
versus time data were fitted with the Hill function by least square 
fitting (MATLAB R2018b, Mathworks). The following parameters 
were calculated: (a) clotting inhibition or delay by anti-TF, defined 
as percentage of patients in whom clotting was either entirely inhib-
ited or at least 10% delayed in presence of anti-TF; (b) clotting time 
delay by anti-TF, defined as clotting time of plasma in absence of 
anti-TF minus clotting time of plasma in presence of anti-TF; and (c) 
OD decrease by anti-TF, defined as OD of plasma in absence of anti-
TF minus OD of plasma in presence of anti-TF, as an indirect measure 
of changes in clot thickness.
3.8.3 | Compliance and response to dual 
antiplatelet therapy
Platelet reactivity in response to dual antiplatelet therapy was 
assessed by multiple electrode aggregometry using the commer-
cially available ASPI test (arachidonic acid, 0.5 mmol/L) and the 
ADP test (ADP, 6.5 µmol/L), respectively.30 The TRAP (thrombin 
receptor-activating peptide-6 [SFLLRN], 32 µmol/L) test was used 
as a positive control. Although ADP released from platelets acti-
vated by TRAP amplifies the response to TRAP, the TRAP test was 
the best available control. Unstimulated whole blood was used as 
a negative control.
3.9 | Statistical analysis
Sample size was calculated based on preliminary in vitro experi-
ments.20 We observed that in the presence of ticagrelor, acti-
vated platelets release two-fold fewer EVs than in the absence 
of ticagrelor. Based on this observation, the required sample size 
was calculated by a two-sided t-test at a significance level of .05 
with the following assumptions: (a) standard deviation (SD) in each 
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group ± 1.0, (b) mean difference between the groups = 1, and (c) 
nominal test power = 0.9. Based on this sample size estimation, a 
total of 46 patients (23 per group) should be enrolled in the study 
to observe a mean difference in the platelet EV concentrations. 
Taking into account that up to 30% of patients can be potentially 
lost to follow-up, 60 patients (30 per group) were included in the 
study.
Statistical analysis was conducted using IBM SPSS Statistics, 
version 24.0 (IBM). Categorical variables were presented as 
number and percent and compared using Fischer's exact test. A 
Shapiro–Wilk test was used to assess normal distribution of con-
tinuous variables. Continuous variables were presented as mean 
and SD or median with interquartile range. Linear regression tak-
ing into account EV concentration at baseline and at 72 hours as 
additional covariates were used to compare the concentrations 
between the two treatment arms at 6 months. All other variables 
were compared using an unpaired t-test or Mann-Whitney U test, 
depending on the data distribution. Differences in variables be-
tween three time points were assessed using a Kruskal–Wallis 
test with Dunn's correction for multiple comparisons. Correlations 
between EV concentrations and platelet reactivity or parameters 
of a fibrin generation test (FGT) were analyzed using a Spearman 
correlation coefficient test. Mortality and other adverse events 
were reported descriptively. A P-value below .05 was considered 
significant.
4  | RESULTS
An exclusion and inclusion chart of the study is shown in Figure 1B. 
Of the 1062 patients who underwent PCI with stent implantation 
between January 2017 and June 2018, 60 patients were randomized 
and 55 patients were included in the final analysis (27 in the ticagre-
lor group and 28 in the clopidogrel group). Patient characteristics are 
presented in Table 2. There were no differences in baseline, clinical, 
and laboratory characteristics between the groups. At hospital dis-
charge after AMI, the mean left ventricle ejection fraction and global 
longitudinal strains, as well as pharmacotherapy, were well balanced 
between the groups. All patients received aspirin; all patients except 
for one received atorvastatin; and more than 90% of patients re-
ceived a β-blocker, an angiotensin-converting enzyme inhibitor, and 
a proton pump inhibitor. All additional orally administered drugs are 
listed in Table S3 in supporting information and were comparable 
between the groups.
4.1 | Concentrations of extracellular vesicles
Figure 2 shows the concentrations of EVs in platelet-depleted plasma, 
measured with flow cytometry at 24 hours and after 72 hours and 
6 months of treatment with ticagrelor or clopidogrel. At 24 hours, 
concentrations of all EV subtypes were comparable between patient 
groups.
Figure 2A shows the concentrations of EVs from activated plate-
lets (CD61+/P-selectin+). After 72 hours, EVs from activated platelets 
were comparable between the patient groups. After 6 months, EVs 
from activated platelets were lower on ticagrelor, compared to clopi-
dogrel. Over time, the concentrations of EVs from activated platelets 
remained stable on ticagrelor and increased two-fold on clopidogrel.
Figure 2B shows the concentrations of EVs from activated 
platelets/aggregates (fibrinogen+). After 72 hours and after 
6 months, the concentrations of fibrinogen+ EVs were lower on 
ticagrelor, compared to clopidogrel. Over time, the concentrations 
of fibrinogen+ EVs increased ~two-fold both on ticagrelor and on 
clopidogrel.
Figure 2C shows the concentrations of EVs from leukocytes 
(CD45+). After 72 hours and after 6 months, the concentrations of 
leukocyte EVs were lower on ticagrelor, compared to clopidogrel. 
Over time, the concentrations of leukocyte EVs increased on tica-
grelor and remained stable on clopidogrel.
Figure 2D shows the concentrations of EVs from ECs (CD31+/
CD146+). After 72 hours and after 6 months, the concentrations of 
EC EVs were comparable between the patient groups. Over time, the 
concentrations of EC EVs did not change.
Figure 2E shows the concentrations of EVs from erythrocytes 
(CD235+; “control EVs”). After 72 hours and after 6 months, the con-
centrations of EVs from erythrocytes were comparable between the 
patient groups. Over time, the concentrations of erythrocyte EVs 
increased two-fold in both patient groups.
4.2 | Procoagulant activity of plasma EVS
Figure 3 shows plasma EV procoagulant activity in patients 
treated with ticagrelor and clopidogrel determined as (a) the con-
centration of all EVs exposing PS measured with flow cytometry 
(Figure 3A), and (b) the TF-dependent procoagulant activity of all 
EVs measured with FGT (Figure 3B-D) at 24 hours, after 72 hours, 
and 6 months.
Figure 3A shows the concentrations of EVs exposing PS (lact-
adherin+). At 24 hours, the concentrations of PS-exposing EVs were 
comparable between the patient groups. After 72 hours and after 
6 months, the concentrations of PS-exposing EVs were lower on 
ticagrelor, compared to clopidogrel. Over time, concentrations of 
PS-exposing EVs increased both on ticagrelor and on clopidogrel.
Figure 3B-D shows the results of FGT: the inhibition (complete 
block) or delay (at least 10% prolongation) of clotting (Figure 3B), the 
amount of clotting time delay in the presence of anti-TF (Figure 3C), and 
the decrease in OD reflecting a change in clot thickness (Figure 3D) in 
the presence of anti-TF. The reproducible results were obtained in 21 
patients on ticagrelor (77%), and 17 patients on clopidogrel (61%). The 
coefficients of variations of the measured parameters were between 
0.01% and 47%. All FGT parameters were comparable between the 
treatment groups both at 24 hours, after 72 hours, and after 6 months. 
None of the parameters changed over time. The examples of the FGT 
clotting curves are included in the Supporting Information.
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TA B L E  2   Patient characteristics (intention-to-treat population)
Characteristic
Ticagrelor (n = 27) Clopidogrel (n = 28) P-value
N SD, range, % N SD, range, % .23
Age, years – mean ± SD 66 10 63 10 .77
Male gender – number (%) 19 70 21 75 .38
BMI – median (IQR) 28 5 29 4 .38
Diagnosis at admission – number (%)
STEMI 18 67 22 79 .38
NSTEMI 9 33 6 21 .76
Administration of morphine at admission 6 22 8 28 .76
Cardiovascular risk factors – number (%)
Arterial hypertension 18 67 18 57 .78
Diabetes mellitus 5 19 5 18 1.00
Dyslipidaemia 18 67 23 82 .23
Smoking 26 96 23 82 .19
History of CVD – number (%)
Stroke 0 0 1 4 1.00
Carotid artery disease 0 0 0 0 1.00
Peripheral artery disease 0 0 3 11 .24
Laboratory characteristics at admission
CK-MB, ng/mL – median (IQR) 16 4-97 37 12-93 .57
Creatinine, mg/dL – median (IQR) 0.9 0.7-1.1 1 0.8-1.1 .56
C-reactive protein – median (IQR) 3 2-6 4 2-6 .75
Haemoglobin, g/dL – mean ± SD 14 1 14 2 .11
INR – median (IQR) 1.1 1.0-1.2 1.1 1.0-1.2 .75
LDL-C – mean ± SD 120 40 127 39 .48
NT-proBNP – median (IQR) 1277 361-2498 628 211-1765 .33
Platelet count, 103/μL – mean (SD) 237 78 245 65 .64
Troponin I, ng/mL – median (IQR) 11 1-35 23 4-37 .24
Echocardiography at discharge      
LVEF, % – median (IQR) 45 27-53 45 35-50 .28
GLS, % – mean ± SD 17.3 4.5 16.2 4.7 .61
Pharmacotherapy at discharge – number (%)
Aspirin 27 100 28 100 1.00
Atorvastatin 27 100 27 96 1.00
β-blocker 25 93 25 89 1.00
ACE-inhibitor or ARB 25 93 28 100 .24
Aldosterone receptor antagonist 7 26 7 25 1.00
Proton pump inhibitor 26 96 26 93 1.00
Pharmacotherapy at 6 mo – number (%)
Aspirin 27 100 28 100 1.00
Atorvastatin 27 100 28 100 1.00
β-blocker 25 93 26 93 1.00
ACE-inhibitor or ARB 25 93 27 96 1.00
Aldosterone receptor antagonist 6 22 5 18 .75
Proton pump inhibitor 89 89 25 89 1.00
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blockers; BMI, body mass index, weight in kilograms divided by 
square of the height in meters; CK-MB, creatine kinase muscle-brain isoenzyme; CVD, cardiovascular disease; GLS, global longitudinal strain; INR, 
international normalized ratio; IQR, interquartile range; LDL-C, low-density lipoprotein-cholesterol; LVEF, left ventricle ejection fraction; NSTEMI, 
non-ST-segment elevation myocardial infarction; NT-proBNP, N-terminal pro-b-type natriuretic peptide; SD, standard deviation; STEMI, ST-segment 
elevation myocardial infarction.
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4.3 | Platelet reactivity
Figure 4 shows platelet reactivity of unstimulated platelets (nega-
tive control), in response to arachidonic acid (response to aspirin), 
ADP (response to P2Y12 antagonists), and TRAP (positive con-
trol) at 24 hours, and after 72 hours and 6 months of treatment 
with ticagrelor or clopidogrel. Platelet reactivity of unstimulated 
platelets, platelets activated with AA, and TRAP was comparable 
at each time point and stable over time (Figure 4A,B,D). Platelet 
reactivity in response to ADP was comparable between patient 
groups at 24 hours, when all patients were treated with clopi-
dogrel. After 72 hours and after 6 months, platelet reactivity in re-
sponse to ADP was lower in patients treated with ticagrelor. Over 
time, platelet reactivity in response to ADP decreased on tica-
grelor (Figure 4C). High-on treatment platelet reactivity (HTPR), 
defined as platelet reactivity >46 aggregation units in response 
to 6.5 μmol/L ADP,31 was observed in one patient on ticagrelor 
(4%) and nine patients on clopidogrel (32%) at 6 months (data not 
shown).
F I G U R E  2   Concentrations of extracellular vesicles (EVs) measured with flow cytometry in platelet-depleted plasma prepared from 
patients treated with ticagrelor and clopidogrel after 24 hours, 72 hours, and 6 months after onset of AMI. We included EVs exceeding the 
side scatter threshold (≥10 nm2), having a diameter >200 nm, having a refractive index <1.42, and being positive for the labelled fluorophore. 
A,B, EVs from activated platelets exposing activation/aggregation markers (CD61 and P-selectin, fibrinogen). C, EVs from leukocytes. D, EVs 
from endothelial cells. E, EVs from erythrocytes
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4.4 | Correlations
Figure 5 shows the correlations between (a) concentrations of EVs 
and platelet reactivity in response to ADP (Figure 5A,C,E) and (b) 
concentrations of EVs and concentration of C-reactive protein 
(CRP; Figure 5B,D,F) after 72 hours of treatment with clopidogrel 
or ticagrelor. In the ticagrelor group, the concentration of EVs from 
activated platelets (CD61+, P-selectin+) correlated with the concen-
tration of CRP (Figure 5B), whereas the concentration of EVs ex-
posing fibrinogen correlated with platelet reactivity (Figure 5C). In 
the clopidogrel group, we did not find any correlations between 
concentrations of EVs and CRP or platelet reactivity in response to 
ADP after 72 hours (Figure 5A-F). We did not find any correlations 
between concentrations of any EV subtype and platelet reactivity in 
response to ADP after 6 months (data not shown).
Figure 6 shows the correlations between (a) concentrations of 
EVs and clotting time delay by anti-TF (Figure 6A,C,E) and (b) con-
centrations of EVs and decrease in OD by anti-TF (Figure 6B,D,F) 
after 72 hours of treatment with clopidogrel or ticagrelor. There 
was a negative correlation between fibrinogen-exposing EVs and 
clotting time delay by anti-TF both on ticagrelor and on clopidogrel 
(Figure 6C), indicating that higher concentration of fibrinogen-ex-
posing EVs is associated with greater procoagulant activity of plasma 
TF-exposing EVs (less inhibition by anti-TF).
4.5 | Clinical outcomes
There were no deaths and no recurrent thrombotic events during the 
study. There were two recurrent hospitalizations: (a) due to exacerba-
tion of heart failure in the ticagrelor group, and (b) due to pneumonia 
in the clopidogrel group. There was one major bleeding event from 
the gynecologic tract in the ticagrelor group and one major bleeding 
event from a diabetic foot ulcer in the clopidogrel group. Both bleed-
ing events were reported to the local authorities and assessed by the 
Steering Committee as unrelated to the study treatment.
4.6 | Compliance
Based on counting of tablets, one patient on ticagrelor (4%) and 
one patient on clopidogrel (4%) temporarily interrupted antiplatelet 
F I G U R E  3   Procoagulant activity of plasma extracellular vesicles (EVs) in platelet-depleted plasma prepared from patients treated with 
ticagrelor and clopidogrel determined as the concentration of phosphatidylserine-exposing EVs (A) and as the ability of EVs to generate 
fibrin in platelet-free, but EV-containing plasma following recalcification (fibrin generation test) in absence and presence of antibody against 
human tissue factor (activated factor VII; B-D). A, includes EVs exceeding the side scatter threshold (≥10 nm2), having a diameter >200 nm, 
having a refractive index <1.42, and being positive for the labelled fluorophore. CT, clotting time; OD, optical density
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therapy due to major bleeding event, as described above. Antiplatelet 
therapy was re-initiated after less than a week, once the cause of 
bleeding had been managed.
5  | DISCUSSION
AFFECT EV is the first clinical study which directly compared the 
long-term effects of P2Y12 antagonists ticagrelor and clopidogrel on 
the concentrations and procoagulant activity of plasma EVs in a ran-
domized and investigator-blinded way. Different P2Y12 antagonists 
added to whole blood or platelet-rich plasma were shown to de-
crease the agonist-induced release of platelet EVs.28,32-36 However, 
the previous evidence was derived from experimental studies28,34 
and one uncontrolled cohort study,37 whereas our study compared 
the effects of ticagrelor and clopidogrel on EV release head-to-head, 
in a randomized and investigator-blinded way. Thus, our study in-
creased the level of evidence of this finding from level C (data de-
rived from small, observational studies) to level B (data derived from 
a single randomized controlled trial).11,21,22 Further, AFFECT EV is 
the first clinical study in which the recently standardized protocols 
and guidelines23,27,38,39 were applied to prevent artefacts and maxi-
mize the reliability and reproducibility of the results. For example, 
we determined the EV diameter and refractive index by Flow-SR,25 
we calibrated all flow cytometry detectors in comparable meas-
urement units and automated data processing to ensure reliability, 
comparability, and reproducibility.38 Thus, we present the first com-
parable EV data in a clinical study.
The main finding of our study is that ticagrelor attenuates the 
increase of platelet (CD61+, P-selectin+), fibrinogen+, PS+, and leuko-
cyte EV concentrations in plasma after acute myocardial infarction 
compared to clopidogrel. The increase in EV exposing P-selectin, fi-
brinogen and PS and EVs from leukocytes over time might at least 
partly explain the 10% of recurrent thrombotic events on ticagrelor 
observed in the PLATO study, as well as the higher rate of recurrent 
thrombotic events on clopidogrel, compared to ticagrelor. It was pre-
viously reported that the aggregation of platelets is a prerequisite 
for EV release.40 Because ticagrelor blocks platelet aggregation to 
a greater extent than clopidogrel, the larger “anti-EV” effect of ti-
cagrelor compared to clopidogrel may be merely due to incomplete 
platelet inhibition by clopidogrel. Indeed, in a recent observational 
study in 38 patients after AMI, patients treated with ticagrelor or 
prasugrel had lower concentrations of P-selectin+ platelet EVs, com-
pared to those treated with clopidogrel.37 Hence, prasugrel might 
have the same effect on EVs as ticagrelor. On the other hand, ti-
cagrelor blocks platelet aggregation via a double pathway (blocking 
the P2Y12 receptor and increasing the concentration of adenos-
ine), whereas clopidogrel and prasugrel block the P2Y12 receptor 
F I G U R E  4   Platelet aggregation in blood collected from patients treated with ticagrelor and clopidogrel; control (unstimulated platelets) 
and in response to arachidonic acid (ASPI test), adenosine diphosphate (ADP test), and thrombin receptor-activating peptide-6 (TRAP test)
Unstimulated platelets (negative control) ASPI test (response to aspirin)
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only.14,41 Because adenosine has both antiplatelet and anti-inflam-
matory effects,12,17,41 adenosine may also contribute to the “an-
ti-EV” effect of ticagrelor. Because we did not measure adenosine 
serum level, we can only speculate about the mechanism underlying 
the inhibition of EV release by ticagrelor.
In patients treated with ticagrelor, the concentrations of EVs 
exposing CD61 and P-selectin correlated with the concentration of 
CRP (r = .42, P = .04), whereas the concentrations of EVs exposing 
fibrinogen correlated with platelet reactivity (r = .49, P = .01), sug-
gesting that EVs exposing P-selectin are indicators of inflammation, 
whereas EVs exposing fibrinogen reflect ongoing thrombosis. In the 
case of ticagrelor, the correlation between fibrinogen-exposing EVs 
and platelet reactivity30,37 suggests that EVs could potentially be 
applied as a tool to monitor antiplatelet therapy. The lack of correla-
tion between P-selectin exposing EVs and CRP in the clopidogrel 
group may result from different effects of ticagrelor and clopidogrel 
on immune signalling.42 In the PLATO study, the concentration of 
CRP was higher on ticagrelor compared to clopidogrel at hospital 
discharge.42 Despite higher CRP concentrations at discharge, pa-
tients treated with ticagrelor had a lower rate of infection-related 
death during a 12-month observation period, suggesting that the 
increase in CRP in the acute phase of AMI paradoxically translates to 
better long-term outcomes. In turn, the lack of correlation between 
fibrinogen exposing EVs and platelet reactivity on clopidogrel may 
be caused by the fact that, in case of ticagrelor, the antiplatelet and 
“anti-EV” effect are associated with each other, whereas in the case 
of clopidogrel the antiplatelet effect is present in most patients and 
the “anti-EV” effect is absent.
Lower concentrations of EVs exposing P-selectin, fibrinogen, and 
PS as well as leukocyte EVs in the acute phase of AMI, compared to 
the later phase, might be due to the fact that the baseline values are 
suppressed by administration of the loading dose of antiplatelet drugs 
and/or anticoagulants in the first 24 hours after AMI. Indeed, in a re-
cent meta-analysis the post-PCI concentrations of platelet EVs were 
F I G U R E  5   Correlations between (a) concentrations of extracellular vesicles (EVs) and platelet reactivity in response to ADP (A, C, E) and 
(b) concentrations of EVs and concentration of C-reactive protein (CRP; B, D, F) after 72 hours of treatment with clopidogrel or ticagrelor
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shown to be 100% lower, compared to the pre-PCI concentrations.3 
Alternatively, EVs may become part of a thrombus during AMI. In 
vitro, perfusion of whole blood over type I collagen decreased the 
concentration of platelet EVs exposing the activated glycoprotein 
IIb-IIIa in post-perfusion blood.43 Further, scanning electron micros-
copy revealed that thrombi expose 0.1-0.5 μm in diameter, granular 
and CD61-positive particles, suggesting that platelet EVs adhere to 
fibrin.44,45 Incorporation of EVs in thrombi in the acute phase of AMI 
may result in a lower concentration of platelet EVs in systemic blood. 
To support this, concentrations of P-selectin+ platelet EVs increased 
over a 2-year follow-up period in 105 patients after AMI.46
Because no placebo group was included in the study due to 
ethical reasons, it cannot be excluded that not only ticagrelor, but 
also clopidogrel, decreases the release of EVs. If present, the “an-
ti-EV effect” of clopidogrel is less compared to ticagrelor. In fact, 
the inhibition of EV release does not seem to be specific for P2Y12 
antagonists. GPIIb/IIIa antagonists (abciximab, tirofiban) also inhibit 
EV release, whereas aspirin does not.40,47 Because (a) ADP-induced 
platelet aggregation is not impaired by aspirin,48 (b) ADP amplifies 
platelet aggregation in response to any platelet agonist,49 and (c) 
binding of fibrinogen to activated GPIIb/IIIa is crucial for platelet ag-
gregation,41 it seems that only blocking ADP-dependent aggregation 
and downstream pathways blocks EV release.
We observed no differences in the concentrations of EC-EVs 
over time and no differences after 72 hours and 6 months between 
the patient groups. In contrast to platelets and leukocytes,17,50 ECs 
have mostly A1 receptors for adenosine, and fewer A2a receptors.19 
The differences in adenosine receptor profiles between platelets/
leukocytes and ECs might explain the lack of effect of the P2Y12 
antagonists on EC-EVs.
In contrast to our expectations, we observed an increase in eryth-
rocyte EVs over time both on ticagrelor and clopidogrel, with no 
F I G U R E  6   Correlations between (a) concentrations of EVs and clotting time delay by anti-TF (A, C, E) and (b) concentrations of EVs and 
decrease in OD by anti-TF (B, D, F) after 72 hours of treatment with clopidogrel or ticagrelor
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differences between the patient groups. Likely, erythrocyte EVs are 
affected either by drugs other than P2Y12 antagonists routinely admin-
istered in the acute phase of AMI (eg, heparin) or after AMI (eg, statins; 
Table 2, Table S3). Other studies focusing specifically on erythrocyte 
EVs are required to explain their increase after AMI and potential effect 
of drugs.
Regarding the procoagulant function of EVs, we did not find changes 
in clotting time and clot thickness in patients treated with ticagrelor, 
compared to clopidogrel. However, because ~30% of the samples were 
excluded from the analysis due to lack of reproducibility, the func-
tional assay results are underpowered and require further exploration. 
Other authors demonstrated that ticagrelor suppresses prothrombotic 
changes in the fibrin clot ultrastructure, compared to clopidogrel, in a 
group of 20 healthy volunteers administered endotoxin.51
6  | LIMITATIONS
The main limitation of our study is the small size and short follow-
up time. Therefore, despite differences in the primary and second-
ary end points between the groups, the results should be interpreted 
with caution. The second limitation is the lack of clinical end points, 
making the results hypothesis generating rather than ultimately prov-
ing that lower concentrations of (platelet) EVs are associated with 
improved prognosis on ticagrelor, or worse prognosis on clopidogrel. 
Furthermore, although the study was investigator-blinded, it was 
open-label to study participants, so that observer (participant) bias 
cannot be excluded. Finally, we assessed the response to aspirin only 
at 6 months, which is less reliable than assessment at each time point.
7  | CONCLUSIONS
We found that ticagrelor attenuates the increase of platelet (CD61+, 
P-selectin+), fibrinogen+, PS+, and leukocyte EV concentrations in 
plasma after acute myocardial infarction compared to clopidogrel. 
Whereas EVs exposing P-selectin correlate with CRP, EVs exposing 
fibrinogen correlate with platelet reactivity. Because platelet EVs 
exposing P-selectin, fibrinogen, and PS are thought to disseminate 
thrombosis and inflammation, the ongoing release of platelet EVs 
despite treatment with clopidogrel or ticagrelor after AMI may ex-
plain recurrent thrombotic events despite antiplatelet therapy, as 
well as worse clinical outcomes on clopidogrel, compared to tica-
grelor. Further studies are needed to establish whether there is an 
association between concentrations of EVs and recurrent throm-
botic events during treatment with P2Y12 antagonists.
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